Kirk Kerr and Lukas Glos, economist at the Center for Drug Evaluation and Research, U.S. Food and Drug Administration,  are publishing in Pharmaceutical Medicine, an article on Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. They come to the conclusion that orphan status per se is not associated with a reduction in the hazard of generic entry and longer effective market exclusivity periods.